# RIPK1 inhibition limits expansion of pathogenic double-negative T cells in preclinical autoimmune lymphoproliferative syndrome models

Source: [science.org](https://www.science.org/doi/abs/10.1126/scitranslmed.aeb1037?af=R) · 2026-11-18 · Medicine
Page: https://themorning.science/story/ripk1-inhibition-limits-expansion-of-pathogenic-double-negative-t-cells-in-precl-c2e49709a93f99d7
Kind: research · Impact: medium

## In brief

- A preclinical study reports that RIPK1 inhibition limits the expansion of pathogenic double-negative T cells in autoimmune lymphoproliferative syndrome models.
- The work was published in Science Translational Medicine, Volume 18, Issue 876, in November 2026.

## Why it matters

It identifies RIPK1 inhibition as a possible way to restrain disease-driving T cells in autoimmune lymphoproliferative syndrome, though the evidence is preclinical.

## Timeline

- 2026-11-18: Study published in Science Translational Medicine

## Coverage

- [RIPK1 inhibition limits expansion of pathogenic double-negative T cells in preclinical autoimmune lymphoproliferative syndrome models](https://www.science.org/doi/abs/10.1126/scitranslmed.aeb1037?af=R) — science.org, 2026-11-18

Tags: ripk1, t cells, autoimmunity, lymphoproliferative syndrome, immunology

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
